PCSK9 and type 2 diabetes mellitus: We found that there was evidence for causal associations between PCSK9 inhibitor instrument and lifetime smoking index [β = 0.02 [95% CI, 0.00, 0.03]; P = 0.028]; waist-to-hip ratio (β = 0.05 [95% CI, 0.03, 0.07]; P = 7.26 × 10−6]; type 2 diabetes risk [OR = 1.28 [95% CI, 1.09–1.51]; P = 0.002].